Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

The problem of early mortality in pneumococcal pneumonia: a study of risk factors

Joaquín Burgos, Manel Luján, M. Nieves Larrosa, M. Luisa Pedro-Botet, Dionisia Fontanals, M. Dolores Quesada, Mayli Lung, Guadalupe Bermudo, Benito Almirante, Vicenç Falcó
European Respiratory Journal 2015 46: 561-564; DOI: 10.1183/09031936.00034415
Joaquín Burgos
1Infectious Diseases Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jburgos@vhebron.net
Manel Luján
2Pneumology Dept, Hospital de Sabadell, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, CIBER Enfermedades Respiratorias (CIBERES), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Nieves Larrosa
3Microbiology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Luisa Pedro-Botet
4Infectious Diseases Unit, Hospital Germans Trias i Pujol de Badalona, Universitat Autònoma de Barcelona, CIBER Enfermedades Respiratorias (CIBERES), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dionisia Fontanals
5Microbiology Dept, UDIAT, Hospital de Sabadell, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Dolores Quesada
6Microbiology Dept, Hospital Germans Trias i Pujol de Badalona, Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayli Lung
3Microbiology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guadalupe Bermudo
2Pneumology Dept, Hospital de Sabadell, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, CIBER Enfermedades Respiratorias (CIBERES), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benito Almirante
1Infectious Diseases Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicenç Falcó
1Infectious Diseases Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Comorbidity and infections by encapsulated serotypes are the main risk factors for death in pneumococcal pneumonia http://ow.ly/KSnlB

To the Editor:

The mortality of pneumococcal pneumonia, and especially the number deaths that occur soon after presentation, remains unacceptably high [1]. In 1964, Austrian and Gold [2] observed that 60% of deaths in patients with invasive pneumococcal pneumonia (IPP) occurred within the first 5 days. Unfortunately, this does not appear to have changed over the subsequent five decades [3].

Different factors related to the mortality of pneumococcal disease have been described, including host factors such as age, comorbidities or immunosuppressive conditions [4], and organism-related factors such as serotype, bacterial load or viral co-infection [3, 5–7]. These factors have all been primarily identified to predict overall mortality, but information regarding the determinants of early mortality is scarce. It has been hypothesised that early deaths are more likely to be due to an inappropriate inflammatory response triggered by Streptococcus pneumoniae than to the micro-organism itself [8]. Thus, the factors that influence the early mortality may differ from those associated with late mortality. We performed the present study in order to assess factors associated with early and late mortality in IPP.

This is a multicentre longitudinal study of adults hospitalised because of IPP in three hospitals in Catalonia, Spain. In these hospitals, all microbiological strains isolated in sterile samples are collected systematically. IPP was diagnosed when a patient had consistent clinical findings plus a new pulmonary infiltrate on chest radiography and isolation of S. pneumoniae in blood and/or pleural fluid cultures. The strains were serotyped by Quellung reaction and/or dot-blot assay. Serotypes were grouped according to high (serotypes 3, 6A, 6B, 9N, 19A, 19F and 23F), medium (9V, 12F, 14 and 22F) and low (1, 4, 5, 7F and 8) serotype-specific case fatality rates [6]. Antibiotic therapy was administered at the discretion of the attending physician and the hospital guidelines. Treatment was considered appropriate if at least one antibiotic administered during the first 48 h showed full sensitivity against the isolated strains. To identify the risk factors for early mortality (death within 5 days of admission), late mortality (hospital mortality >5 days after admission) and survival, a multinomial logistic regression analysis was performed.

Over the study period (from 1996 to 2013), 1588 consecutive adults with IPP were diagnosed. Overall, 221 patients (13.9%) died in hospital. 121 (54.5%) died in the first 5 days after admission; 80 (36.1%) of them died in the first 48 h. Patients with early mortality were older (mean age 67.1 years) and 65.5% had an underlying chronic medical illness. At presentation, 91.8% of these cases had respiratory failure, 68.9% septic shock and 37% required intensive care unit admission.

1328 (83.6%) pneumococcal strains were available for serotyping. The pneumococcal serotypes most commonly associated with mortality were serotypes/serogroups 3, 6 and 19F (early and late mortality developed, respectively, in 11.3% and 11.3% of infections by serotype 3, 14.3% and 7.1% by serogroup 6, and 22.2% and 14.8% by serotype 19F).

1300 patients (98.8%) received appropriate empirical therapy. β-lactams associated with macrolide were used in 28.2% of patients. No difference in mortality was observed in relation to the use of macrolide combination.

In the multivariate analysis, after adjustment by age, sex, different comorbidities and pneumococcal vaccine status, the independent risk factors for early mortality were: heavy alcohol consumption (relative risk ratio (RRR) 2.28), chronic heart disease (RRR 2.71), chronic neurological disease (RRR 2.26) and infection caused by high case fatality rate serotypes (RRR 1.98). The risk factors for late mortality were: heavy alcohol consumption (RRR 2.25), HIV infection (RRR 4), haematological cancer (RRR 3.06) and solid cancer (RRR 4.17) (table 1). When we included the specific serotypes in the model, the only serotypes associated were: infection by serotype 19F as a risk factor for early (RRR 5.88, 95% CI 1.69–20.48) and late (RRR 6.44, 95% CI 1.82–22.85) mortality, infection by serotype 3 as a risk factor for late mortality (RRR 2.77, 95% CI 1.32–5.82) and infection by serotype 1 as a protective factor against both early (RRR 0.1, 95% CI 0.02–0.87) and late (RRR 0.12, 95% CI 0.03–0.84) mortality. When we restricted the analysis to non-immunocompromised patients only (n=1010), risk factors for early mortality did not change (data not shown). In the subgroup of immunocompromised patients (n=578), the only risk factor for early mortality was high case fatality rate serotypes (RRR 2.937, 95% CI 0.996–8.660).

View this table:
  • View inline
  • View popup
TABLE 1

Multivariate analysis: risk factors for early and late mortality in invasive pneumococcal pneumonia

The results of this large study of adults with IPP show that the proportion of deaths occurring in the first 5 days remains unacceptably high, above 50% of total deaths. Furthermore, the determinants of early mortality seem to be different from the factors predisposing to later mortality.

In our study, serotypes grouped as having a high case fatality rate were found to be a significant risk factor for early mortality. The association of specific serotypes and mortality has been reinforced in recent years [4–6]. Nevertheless, several authors continue to assert that mortality is primarily associated with host factors [3, 7]. In our view, the results of this study reinforce the idea that micro-organisms are also an important determinant of mortality. The association of these serotypes and early mortality could be connected to the hypothesis that early deaths are due to an inappropriate inflammatory response from the host. Serotypes with high case fatality rates have been found to be heavily encapsulated [6, 9] and induce a greater inflammatory response [10]. Nevertheless, we have also in mind that this phenomenon is complex and probably involves many other factors not entirely explained [11].

In addition to pathogen-related factors, host aspects also play a role in the severity of the illness. Different studies have found that increased age, alcohol abuse, smoking, chronic medical illness, and immunosuppressive conditions were associated with an increased risk of mortality [4, 7, 12]. However, few studies have addressed the relationship between comorbidities and early mortality [3, 13]. In our study, we found that chronic heart disease and severe neurological disease were independent risk factors for early mortality. In contrast, some immunosuppressive conditions carried a high risk of later mortality. The reasons for different factors being associated with different stages of mortality are not clearly understood. We can hypothesise that, although some immunodeficiency conditions may promote pneumococcal infection, they may also decrease the inflammatory response of the host to this infection. If so, this seems more likely to contribute to late mortality than early mortality, which is more related to inflammatory mechanisms.

Studies report conflicting results concerning the benefit of combination antibiotics in pneumococcal pneumonia [14, 15]. We did not find any differences in the mortality attributable to the use of combination therapy with macrolides. This evidence reinforces the hypothesis that early deaths are less dependent on antibiotic than other factors [2].

Our study has some limitations. First, the study included only patients with IPP, and therefore it is difficult to generalise the findings to all cases of pneumococcal pneumonia. Secondly, other factors that might modulate the clinical presentation of pneumococcal pneumonia, such as the genetic properties of S. pneumoniae or the host, or the effect of viral co-infections, have not been evaluated [5]. Finally, we have not evaluated the inflammatory response of the host or anti-inflammatory therapy, so we cannot fully support our hypothesis concerning the effect of encapsulated serotypes or immunosuppressive conditions on mortality.

Despite these limitations, our study demonstrated that early mortality remains a problem in pneumococcal pneumonia, but its determinants differ from factors associated to later mortality.

Footnotes

  • Conflict of interest: None declared.

  • Received January 26, 2015.
  • Accepted March 16, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Varon E,
    2. Mainardi JL,
    3. Gutmann L
    . Streptococcus pneumoniae: still a major pathogen. Clin Microbiol Infect 2010; 16: 401.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Austrian R,
    2. Gold J
    . Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60: 759–776.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Ricketson LJ,
    2. Nettel-Aguirre A,
    3. Vanderkooi OG, et al.
    Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS One 2013; 8: e71924.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Alanee SR,
    2. McGee L,
    3. Jackson D, et al.
    Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007; 45: 52–54.
    OpenUrlFREE Full Text
  5. ↵
    1. Burgos J,
    2. Larrosa MN,
    3. Martinez A, et al.
    Impact of influenza season and environmental factors on the clinical presentation and outcome of invasive pneumococcal disease. Eur J Clin Microbiol Infect Dis 2015; 34: 177–186.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Weinberger DM,
    2. Harboe ZB,
    3. Sanders EA, et al.
    Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51: 692–699.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Naucler P,
    2. Darenberg J,
    3. Morfeldt E, et al.
    Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013; 68: 571–579.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Vernatter J,
    2. Pirofski LA
    . Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis 2013; 26: 277–283.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Weinberger DM,
    2. Trzcinski K,
    3. Lu Y-J, et al.
    Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009; 5: e1000476.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Weiser JN,
    2. Kapoor M
    . Effect of intrastrain variation in the amount of capsular polysaccharide on genetic transformation of Streptococcus pneumoniae: implications for virulence studies of encapsulated strains. Infect Immun 1999; 67: 3690–3692.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Sanchez CJ,
    2. Hinojosa CA,
    3. Shivshankar P, et al.
    Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One 2011; 6: e26587.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Klemets P,
    2. Lyytikainen O,
    3. Ruutu P, et al.
    Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008; 8: 96.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Marrie TJ,
    2. Wu L
    . Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127: 1260–1270.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Aspa J,
    2. Rajas O,
    3. Rodriguez de Castro F, et al.
    Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27: 1010–1019.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Martinez JA,
    2. Horcajada JP,
    3. Almela M, et al.
    Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389–395.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 46 Issue 2 Table of Contents
European Respiratory Journal: 46 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The problem of early mortality in pneumococcal pneumonia: a study of risk factors
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The problem of early mortality in pneumococcal pneumonia: a study of risk factors
Joaquín Burgos, Manel Luján, M. Nieves Larrosa, M. Luisa Pedro-Botet, Dionisia Fontanals, M. Dolores Quesada, Mayli Lung, Guadalupe Bermudo, Benito Almirante, Vicenç Falcó
European Respiratory Journal Aug 2015, 46 (2) 561-564; DOI: 10.1183/09031936.00034415

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The problem of early mortality in pneumococcal pneumonia: a study of risk factors
Joaquín Burgos, Manel Luján, M. Nieves Larrosa, M. Luisa Pedro-Botet, Dionisia Fontanals, M. Dolores Quesada, Mayli Lung, Guadalupe Bermudo, Benito Almirante, Vicenç Falcó
European Respiratory Journal Aug 2015, 46 (2) 561-564; DOI: 10.1183/09031936.00034415
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society